Cryo-EM has enabled new possibilities for structure-based drug design of GPCR agonists. Workflows are now mature for every step from protein to structure. There are limitations in commercial applications, however, for some approaches in stabilizing active GPCR structures. Our GPCR/G-protein complex-stabilizing scFv Recombinant Mouse Monoclonal Antibody (scFv16) offers a license-free and broadly applicable solution for determining structures of active GPCRs. Initially designed for Gi complexes, this antibody fragment can be used for other G-protein subfamilies with small adaptation to the sequence of the G alpha subunit. Most importantly, scFv16 can be used to support commercial structure-based drug design projects.
Interested in speaking with a scientist about scFv16 or GPCR cryo-EM?
Please subscribe below and let us know how you would like to be contacted.